Axinn Counsel Stacie Ropka presented at a webinar entitled, “HCT/P: FDA’s Newest Regulatory Battleground.” She provided an exclusive analysis of the FDA oversight of HCT/Ps with a focus on what the draft guidelines mean to manufacturers.